Investigational drugs in development for focal segmental glomerulosclerosis.

about

Investigational drugs in development for focal segmental glomerulosclerosis.

Item

http://www.wikidata.org/entity/Q51840896

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Investigational drugs in development for focal segmental glomerulosclerosis.

@en

Investigational drugs in development for focal segmental glomerulosclerosis.

@nl

type

Item

label

Investigational drugs in development for focal segmental glomerulosclerosis.

@en

Investigational drugs in development for focal segmental glomerulosclerosis.

@nl

prefLabel

Investigational drugs in development for focal segmental glomerulosclerosis.

@en

Investigational drugs in development for focal segmental glomerulosclerosis.

@nl

P1476

Investigational drugs in development for focal segmental glomerulosclerosis.

@en

P2860

Familial focal segmental glomerulosclerosis (FSGS)-linked α-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View

A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues

Systems biology analysis reveals role of MDM2 in diabetic nephropathy

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

P304

945-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1351544

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Howard Trachtman

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28707483

http://www.w3.org/2001/XMLSchema#string